Alibaba jumps 4% in premarket after it completes three-year regulatory overhaul

Alibaba jumps 4% in premarket after it completes three-year regulatory overhaul


The Alibaba office building is seen in Nanjing, Jiangsu province, China, Aug 28, 2024. 

CFOTO | Future Publishing | Getty Images

Alibaba has completed a three-year regulatory “rectification” process following an antitrust fine it received on charges of monopolistic practices in 2021, China’s market regulator said on Friday.

Shares of Alibaba rose 4.37% at 07:24 a.m. in premarket trading in the U.S.

On Friday, China’s State Administration for Market Regulation (SAMR) said that, over the past few years, it has been supervising Alibaba’s process to become compliant with antitrust regulations. The rectification work has achieved “good results,” the SAMR said, according to a Google-translated statement.

In 2021, China’s SAMR fined Alibaba 18.23 billion yuan ($2.6 billion) as part of an anti-monopoly investigation into the tech giant. The regulator’s focus was on a practice that forces merchants to choose one of two e-commerce platforms, rather than being able to work with both.

At the time, the regulator said that the “choose one” policy and others allowed Alibaba to bolster its position in the market and gain unfair competitive advantages.

Since that fine, the SAMR has been supervising Alibaba as it gets in line with the regulator’s requirements. Alibaba has now completed this process and has stopped the “‘choose one of two’ monopoly behavior,” the SAMR said Friday.

The SAMR said it will now guide Alibaba to continue to improve its compliance and efficiency and to accelerate innovation.

The conclusion of the regulatory overhaul will help put one of Alibaba’s worst run-ins with Beijing behind it. Jefferies analysts said in a note on Friday that the conclusion of the regulatory process was a “positive” for the company, which “highlights this is a new start and ensures compliance in operations.”

But the regulator’s announcement could also signal the ongoing softening stance from Chinese regulators towards private technology firms, following an intense crackdown that began at the end of 2020. At the time, Beijing enacted several regulations and moves that aimed to restrict the power of domestic technology firms in areas ranging from antitrust to gaming.

The empire of Alibaba founder Jack Ma has been in the spotlight over the past few years since regulators axed the IPO of his financial technology firm Ant Group in 2020. Ant Group itself also underwent a regulator-supervised rectification process, with most of the major issues resolved by last year.

Regulatory concerns have been an overhang on the Alibaba stock, which has fallen more than 70% from its peak in 2020. More recently, the company has been dealing with slow growth amid rising competition in the e-commerce space in China, as well as contending with a cautious Chinese consumer.

The tech titan showed early signs of a recovery in the June quarter, as cloud computing revenue reaccelerated and transactions via its e-commerce platforms looked healthy.

CNBC’s Christine Wang contributed to this report.



Source

CEOs are betting AI will augment work rather than displace all workers
World

CEOs are betting AI will augment work rather than displace all workers

The effect artificial intelligence will have on the labor market has left workers and job seekers alike worried about their future. Top executives, however, are optimistic that the technology can continue to augment workloads rather than entirely displace human employees. The debate over the future of work even extends inside the corridors of a major […]

Read More
J&J tops first-quarter profit estimates even as Stelara sales plunge
World

J&J tops first-quarter profit estimates even as Stelara sales plunge

Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara. And the company expressed confidence in its just-approved once-daily, oral psoriasis treatment, Icotyde, saying about 1,500 […]

Read More
Iran war will hit UK growth the hardest of any rich economies, IMF says
World

Iran war will hit UK growth the hardest of any rich economies, IMF says

The U.K. will suffer the biggest hit to growth of all of the world’s richest economies because of the Iran war, the International Monetary Fund warned on Tuesday. In its latest World Economic Outlook, the IMF projected that the U.K. economy will now grow by just 0.8% in 2026, down from 2025’s 1.3% projection. That’s […]

Read More